News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
745,793 Results
Type
Article (43996)
Company Profile (313)
Press Release (701465)
Multimedia
Podcasts (121)
Webinars (22)
Section
Business (211055)
Career Advice (2110)
Deals (36770)
Drug Delivery (132)
Drug Development (83474)
Employer Resources (176)
FDA (16874)
Job Trends (15516)
News (357548)
Policy (34146)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2628)
Accelerated approval (42)
Adcomms (27)
Allergies (164)
Alliances (51587)
ALS (194)
Alzheimer's disease (1755)
Antibody-drug conjugate (ADC) (373)
Approvals (17181)
Artificial intelligence (610)
Autoimmune disease (220)
Automation (49)
Bankruptcy (372)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (205)
Biotechnology (187)
Bladder cancer (175)
Brain cancer (66)
Breast cancer (691)
Cancer (5320)
Cardiovascular disease (450)
Career advice (1793)
Career pathing (39)
CAR-T (296)
CDC (56)
Celiac Disease (2)
Cell therapy (801)
Cervical cancer (40)
Clinical research (71701)
Collaboration (1920)
Company closure (4)
Compensation (1256)
Complete response letters (77)
COVID-19 (2797)
CRISPR (104)
C-suite (982)
Cystic fibrosis (150)
Data (6955)
Decentralized trials (3)
Denatured (37)
Depression (152)
Diabetes (550)
Diagnostics (6903)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (293)
Drug pricing (209)
Drug shortages (32)
Duchenne muscular dystrophy (268)
Earnings (92690)
Editorial (62)
Employer branding (21)
Employer resources (155)
Events (121179)
Executive appointments (1050)
FDA (20273)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (28)
Funding (1604)
Gene editing (217)
Generative AI (51)
Gene therapy (669)
GLP-1 (1053)
Government (4834)
Grass and pollen (7)
Guidances (396)
Healthcare (19095)
HIV (72)
Huntington's disease (52)
IgA nephropathy (90)
Immunology and inflammation (276)
Immuno-oncology (81)
Indications (155)
Infectious disease (3105)
Inflammatory bowel disease (207)
Inflation Reduction Act (14)
Influenza (126)
Intellectual property (273)
Interviews (327)
IPO (16926)
IRA (57)
Job creations (4072)
Job search strategy (1499)
JPM (65)
Kidney cancer (18)
Labor market (92)
Layoffs (580)
Leadership (36)
Legal (8425)
Liver cancer (97)
Longevity (29)
Lung cancer (711)
Lymphoma (406)
Machine learning (53)
Management (60)
Manufacturing (926)
MASH (180)
Medical device (13923)
Medtech (13999)
Mergers & acquisitions (20989)
Metabolic disorders (1427)
mRNA (182)
Multiple sclerosis (171)
NASH (18)
Neurodegenerative disease (381)
Neuropsychiatric disorders (98)
Neuroscience (3150)
Neurotech (1)
NextGen: Class of 2026 (6646)
Non-profit (4572)
Now hiring (73)
Obesity (677)
Opinion (299)
Ovarian cancer (180)
Pain (240)
Pancreatic cancer (253)
Parkinson's disease (336)
Partnered (34)
Patents (552)
Patient recruitment (576)
Peanut (63)
People (61210)
Pharmaceutical (86)
Pharmacy benefit managers (33)
Phase 1 (22256)
Phase 2 (31535)
Phase 3 (23620)
Pipeline (6862)
Policy (318)
Postmarket research (2655)
Preclinical (9460)
Press Release (68)
Prostate cancer (274)
Psychedelics (51)
Radiopharmaceuticals (307)
Rare diseases (1003)
Real estate (6308)
Recruiting (72)
Regulatory (25782)
Reports (54)
Research institute (2454)
Resumes & cover letters (362)
Rett syndrome (32)
RNA editing (18)
RSV (85)
Schizophrenia (166)
Series A (271)
Series B (200)
Service/supplier (11)
Sickle cell disease (107)
Special edition (25)
Spinal muscular atrophy (163)
Sponsored (45)
Startups (3775)
State (2)
Stomach cancer (19)
Supply chain (118)
Tariffs (96)
The Weekly (82)
Vaccines (1074)
Venture capital (100)
Weight loss (436)
Women's health (109)
Worklife (19)
Date
Today (35)
Last 7 days (616)
Last 30 days (2774)
Last 365 days (30402)
2026 (7461)
2025 (30678)
2024 (35762)
2023 (40629)
2022 (51799)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38616)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (801)
Alabama (88)
Alaska (7)
Arizona (335)
Arkansas (15)
Asia (42355)
Australia (6784)
California (12194)
Canada (3498)
China (1244)
Colorado (518)
Connecticut (518)
Delaware (366)
Europe (90982)
Florida (1835)
Georgia (387)
Hawaii (3)
Idaho (61)
Illinois (964)
India (80)
Indiana (561)
Iowa (22)
Japan (490)
Kansas (130)
Kentucky (44)
Louisiana (37)
Maine (73)
Maryland (1481)
Massachusetts (8757)
Michigan (347)
Minnesota (670)
Mississippi (6)
Missouri (136)
Montana (33)
Nebraska (29)
Nevada (134)
New Hampshire (82)
New Jersey (3245)
New Mexico (29)
New York (3212)
North Carolina (1563)
North Dakota (8)
Northern California (6016)
Ohio (361)
Oklahoma (23)
Oregon (46)
Pennsylvania (2464)
Puerto Rico (25)
Rhode Island (50)
South America (1178)
South Carolina (74)
South Dakota (1)
Southern California (4783)
Tennessee (197)
Texas (1911)
United States (43279)
Utah (365)
Vermont (1)
Virginia (304)
Washington D.C. (80)
Washington State (982)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
745,793 Results for "agios pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
March 2, 2026
·
14 min read
Press Releases
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 12, 2026
·
10 min read
Regulatory
Report of Patient Deaths Sends Agios Shares Seesawing
While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an SEC filing midday Monday that the drug’s risk-benefit profile remains unchanged.
August 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
December 8, 2025
·
4 min read
Business
JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals
Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, setting both revenue and R&D targets through the end of the decade.
January 14, 2026
·
4 min read
·
Tristan Manalac
Press Releases
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
January 12, 2026
·
10 min read
Press Releases
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
January 5, 2026
·
1 min read
Press Releases
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
January 27, 2026
·
1 min read
Press Releases
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
December 24, 2025
·
15 min read
Press Releases
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
October 20, 2025
·
10 min read
1 of 74,580
Next
